Clinical Trials Browser

Clear Cell Tumor

Clear-cell metastatic renal cell carcinoma

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Lymphoma, Lymphoma, Non-Hodgkin

Head and Neck Neoplasms

Carcinoma, Hepatocellular

Muscle Invasive Bladder Urothelial Carcinoma

Brain Neoplasms

Diabetes Mellitus

Carcinoma, Non-Small-Cell Lung

Melanoma, Neoplasms

Oligometastatic Renal Cell Carcinoma

Hodgkin Disease

Colorectal Cancer Metastatic

Hodgkin Disease

Carcinoma, Renal Cell, Kidney Neoplasms

Ovarian Neoplasms

Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Mesothelioma, Malignant

Vulvar Neoplasms, Neoplasms, Squamous Cell

Colorectal Neoplasms

Kidney Neoplasms, Lung Neoplasms, Melanoma

Squamous Cell Carcinoma of Head and Neck, Deglutition Disorders, Head and Neck Neoplasms, Oropharyngeal Neoplasms

Carcinoma, Hepatocellular

Squamous Cell Carcinoma of Head and Neck

Fallopian Tube Neoplasms, Ovarian Neoplasms

Glioblastoma

Breast Neoplasms

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma

NSCLC With COPD

Carcinoma, Renal Cell, Melanoma

Carcinoma, Non-Small-Cell Lung

Uterine Cervical Neoplasms

PD-1 Antibody

Neoadjuvant Therapy

Carcinoma, Hepatocellular, Liver Neoplasms

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

Colorectal Neoplasms

Liver Neoplasms, Neoplasms, Hepatoblastoma

Breast Neoplasms

Stomach Neoplasms

Neoplasm Metastasis, Pancreatic Neoplasms

Squamous Cell Carcinoma of Head and Neck

Triple Negative Breast Neoplasms

Carcinoma, Hepatocellular

Fallopian Tube Neoplasms, Ovarian Neoplasms

Carcinoma, Non-Small-Cell Lung

MSI-H Advanced Colorectal Cancer

Clinical Trials

PEACOCC

Pembrolizumab Plus Radiotherapy for Advanced Renal Cancer

Vaccination With Flt3L, Radiation, and Poly-ICLC

Concomitant Immune Check Point Inhibitor With Radiochemotherapy in Head And Neck Cancer

Longitudinal Immune-phenotyping of HCC Following MK-3475

Drug Screening Using IMD in Bladder Cancer

TREATMENT

NSCLC

Imatinib Mesylate in Combination With Pembrolizumab in Patients With Melanoma

I-STOP

Neo Trio

PE-PE

PLIMATH

POCHI

Pembrolizumab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

KEYPAD

MITO28MaNGOov4

Pembrolizumab Plus Pemetrexed for Elderly Patients With Non-Sq NSCLC With PD-L1 < 50%: CJLSG1901

Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC)

MiST

Apollo

Nivolumab and Pembrolizumab Dose Optimisation in Solid Tumours With CURATE.AI Platform and Sequential ctDNA Measurements

PEMBROLA

Microbiome Immunotherapy Toxicity and Response Evaluation

QUASAR

Pembrolizumab Plus Y90 Radioembolization in HCC Subjects

PROBES

PROMPT

Neoadjuvant Chemoimmunotherapy in Recurrent Glioblastoma

A Phase II Study Evaluating the Efficacy and Safety of Pembrolizumab in Combination With Chemotherapy as Neoadjuvant Therapy for Triple-negative Breast Cancer

Pembrolizumab and Photodynamic Therapy in Previously Treated Metastatic Esophageal Squamous Cell Carcinoma

Pembrolizumab as First-line Treatment for Advanced NSCLC Complicated With COPD

REFINE

Luscid

Pembrolizumab Plus Olaparib in Patients With Recurrent Cervical Cancer

Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive Carcinoma

The Clinical Efficacy of Drug Sensitive Neoadjuvant Chemotherapy Based on Organoid Versus Traditional Neoadjuvant Chemotherapy in Advanced Rectal Cancer

iPLENTY-pvtt

Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian Cancer

Pembrolizumab and Disitamab Vedotin in HER2-expressing Metastatic Colorectal Cancer

sPLENTY-pc

Pembrolizumab in Combination With Paclitaxel in the Hormone Receptor-positive Metastatic Breast Cancer With High Tumor Mutational Burden Selected by Whole Exome Sequencing: Korean Cancer Study Group Trial (KCSG BR20-16)

Pembrolizumab Plus Ramucirumab in Metastatic Gastric Cancer

EPIC-1

FOCUS

c-TRAK-TN

HAIC Combined With Second-line "Target Immunity" for HCC With TACE Standard Treatment Low Response or Failure

MITO 27

Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC

PD-1 Inhibitor Combined With Bevacizumab and FOLFIRI Regimen in the Second-line Treatment of Advanced Colorectal Cancer